Dapagliflozin: A Key Pharmaceutical Intermediate
Explore the therapeutic potential and applications of this vital compound in modern medicine.
Get a Quote & SampleProduct Core Value
Dapagliflozin Powder
Dapagliflozin is a high-purity pharmaceutical intermediate and API renowned for its efficacy in managing type 2 diabetes. It acts by inhibiting the sodium-glucose cotransporter 2 (SGLT2) in the kidneys, leading to increased urinary glucose excretion and subsequent reduction in blood sugar levels. Beyond its primary role in glycemic control, Dapagliflozin has demonstrated significant benefits in reducing the risk of hospitalization for heart failure and slowing the progression of chronic kidney disease, establishing it as a versatile therapeutic agent.
- Dapagliflozin pharmaceutical intermediate plays a crucial role in the synthesis of advanced medications for metabolic disorders.
- Discover how dapagliflozin API uses extend beyond diabetes to cardiovascular and renal health support.
- Learn about the dapagliflozin mechanism of action, focusing on its SGLT2 inhibition pathway.
- Explore the dapagliflozin side effects and precautions to ensure safe and effective therapeutic use.
Key Advantages
Comprehensive Therapeutic Applications
Dapagliflozin offers multifaceted benefits, not only improving blood sugar control in type 2 diabetes but also showing promise in treating heart failure and chronic kidney disease, making it a cornerstone in modern pharmacotherapy.
High Purity and Quality
Our dapagliflozin 99% powder ensures superior quality for pharmaceutical research and manufacturing, guaranteeing reliable results and therapeutic outcomes.
Enhanced Patient Outcomes
The drug's ability to reduce cardiovascular events and slow kidney disease progression offers significant advantages, leading to improved long-term health for patients.
Key Applications
Type 2 Diabetes Management
As an SGLT2 inhibitor, Dapagliflozin effectively lowers blood glucose levels, improving glycemic control for adults and children (10 years and older) with type 2 diabetes when combined with diet and exercise.
Heart Failure Treatment
For individuals with type 2 diabetes and heart disease or cardiovascular risk factors, Dapagliflozin is proven to lower the risk of hospitalization due to heart failure.
Chronic Kidney Disease Support
Dapagliflozin plays a vital role in slowing the decline of kidney function and reducing the risk of kidney failure in patients with chronic kidney disease.
Scientific Research
The availability of dapagliflozin research grade powder supports ongoing studies and development in metabolic and cardiovascular diseases.